Fructosyl Amino Oxidase as a Therapeutic Enzyme in Age-Related Macular Degeneration.
age-related macular degeneration
ageing
fructosyl amino oxidase
glycation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
31
01
2024
revised:
14
04
2024
accepted:
24
04
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
11
5
2024
Statut:
epublish
Résumé
Age-related macular degeneration (AMD) is an age-related disorder that is a global public health problem. The non-enzymatic Maillard reaction results in the formation of advanced glycation end products (AGEs). Accumulation of AGEs in drusen plays a key role in AMD. AGE-reducing drugs may contribute to the prevention and treatment of AGE-related disease. Fructosamine oxidase (FAOD) acts on fructosyl lysine and fructosyl valine. Based upon the published results of fructosamine 3-kinase (FN3K) and FAOD obtained in cataract and presbyopia, we studied ex vivo FAOD treatment as a non-invasive AMD therapy. On glycolaldehyde-treated porcine retinas, FAOD significantly reduced AGE autofluorescence (
Identifiants
pubmed: 38732004
pii: ijms25094779
doi: 10.3390/ijms25094779
pii:
doi:
Substances chimiques
Glycation End Products, Advanced
0
amadoriase
EC 1.5.3.-
Amino Acid Oxidoreductases
EC 1.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : IOF Ghent University
ID : F2020/IOF-StarTT/034) IOF StarTT-project